Author:

Keywords:

zafirlukast, oral pathogens, biofilms, Porphyromonas gingivalis, Streptococcus mutans, Science & Technology, Life Sciences & Biomedicine, Microbiology, Zafirlukast, PERIODONTAL PATHOGENS, ANTIBIOTIC-RESISTANCE, PERI-IMPLANTITIS, INFECTIONS, MECHANISMS, BIOFILMS, Anti-Asthmatic Agents, Anti-Bacterial Agents, Biofilms, Cell Line, Cell Survival, Drug Repositioning, Humans, Indoles, Microbial Sensitivity Tests, Osteoblasts, Phenylcarbamates, Sulfonamides, Tosyl Compounds, 06 Biological Sciences, 07 Agricultural and Veterinary Sciences, 11 Medical and Health Sciences, 30 Agricultural, veterinary and food sciences, 31 Biological sciences, 32 Biomedical and clinical sciences

Abstract:

Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long-term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the anti-asthma drug zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of zafirlukast to be used as a new antibiotic against oral pathogens.